Calidi Biotherapeutics Receives Compliance Warning from NYSE
Calidi Biotherapeutics (CLDI) received a compliance notice from the NYSE American for failing to meet the $4 million minimum stockholders’ equity requirement. The warning does not immediately affect trading, and shares will continue to be listed on the exchange. The company has until December 2025 to regain compliance by either increasing its shareholders' equity or meeting other listing criteria set forth by NYSE American regulations.
Topics: minimum equity requirement NYSE American stock compliance